Description

Lunsumio (Mosunetuzumab)

Generic Name

Mosunetuzumab-axgb

Brand Name

Lunsumio

Therapeutic Class

Bispecific CD20-directed CD3 T-cell engager monoclonal antibody

Indication

Lunsumio is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy.

Mechanism of Action

Mosunetuzumab is a bispecific antibody that binds to CD20 on B cells and CD3 on T cells. By bringing T cells into close proximity with malignant B cells, it promotes T-cell–mediated destruction of cancer cells.

Dosage and Administration

Lunsumio is administered intravenously using a step-up dosing schedule to reduce the risk of cytokine release syndrome (CRS). Treatment is given in 21-day cycles with escalating doses during Cycle 1 followed by maintenance dosing in subsequent cycles.

Common Adverse Reactions

• Cytokine release syndrome (CRS)
• Neutropenia
• Rash
• Upper respiratory tract infections
• Fatigue
• Fever

Serious adverse reactions may include neurologic toxicity, severe infections, cytopenias, and tumor flare.

Warnings and Precautions

Lunsumio carries a boxed warning for cytokine release syndrome (CRS), which can be serious or life-threatening. Patients should be monitored closely during treatment, particularly during the initial dosing period.

Clinical Efficacy

In clinical studies involving patients with relapsed or refractory follicular lymphoma, approximately 80% of patients achieved an objective response, with about 60% achieving a complete response.

Storage

Store refrigerated at 2°C–8°C. Do not freeze. Protect from light and handle according to product labeling.